Continuation Study for Latozinemab

Status Enrolling by invitation

Clinical Trial Summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Clinical Trial Description

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study. All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w). ;

Study Design

Related Conditions & MeSH terms

Neurodegenerative Diseases

Clinical Trial Details

NCT number	NCT06111014
Study type	Interventional
Source	Alector Inc.
Contact
Status	Enrolling by invitation
Phase	Phase 3
Start date	December 8, 2023
Completion date	November 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05538455` - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases	N/A
Completed	`NCT05788133` - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.	N/A
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Completed	`NCT03295786` - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1/Phase 2
Recruiting	`NCT04265482` - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting	`NCT02222779` - Quantification of Transition Metals	N/A
Recruiting	`NCT01291550` - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples	N/A
Completed	`NCT01450891` - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease	N/A
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Recruiting	`NCT06148233` - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging	N/A
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Completed	`NCT06251830` - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting	`NCT04472130` - Neurodegenerative Diseases Registry
Completed	`NCT03353207` - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed	`NCT05095870` - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting	`NCT05784090` - Correlation Between Melatonin Levels in Different Biological Fluids
Completed	`NCT02108769` - Yogic Breathing Changes Salivary Components	N/A
Recruiting	`NCT05508789` - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	Phase 3
Recruiting	`NCT04820881` - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
Recruiting	`NCT05235802` - Long-term Follow-up in Severe Traumatic Brain Injury